for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Mayne Pharma Group Ltd

MYX.AX

Latest Trade

0.30AUD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

0.26

 - 

0.59

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.30
Open
--
Volume
--
3M AVG Volume
81.26
Today's High
--
Today's Low
--
52 Week High
0.59
52 Week Low
0.26
Shares Out (MIL)
1,764.84
Market Cap (MIL)
520.63
Forward P/E
-40.25
Dividend (Yield %)
--

Next Event

Mayne Pharma Group Ltd Annual Shareholders Meeting

Latest Developments

More

Mayne Pharma Says Frank Condella To Be Named Chairman

Mayne Pharma Group Says Co Served With A Class Action Proceeding In Supreme Court Of Victoria

Mithra, Mayne Pharma's Nextstellis Receives FDA Marketing Exclusivity

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Mayne Pharma Group Ltd

Mayne Pharma Group Ltd is an Australia-based specialty pharmaceutical company focused on commercializing novel and generic pharmaceuticals. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

Industry

Biotechnology & Drugs

Contact Info

1538 Main North Rd

ADELAIDE, SA

5106

Australia

+61.8.82092666

http://www.maynepharma.com/

Executive Leadership

Scott Anthony Richards

Chief Executive Officer, Managing Director, Executive Director

Peter Paltoglou

Chief Financial Officer, Chief Development Officer

Laura Loftus

Company Secretary

Patrick J. Blake

Independent Non-Executive Director

Frank C. Condella

Independent Non-Executive Director

Key Stats

2.14 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2019

0.5K

2020

0.5K

2021

0.4K

2022(E)

0.5K
EPS (AUD)

2019

0.009

2020

0.014

2021

0.011

2022(E)

-0.007
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.30
Price To Book (MRQ)
0.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
45.14
LT Debt To Equity (MRQ)
38.10
Return on Investment (TTM)
-14.71
Return on Equity (TTM)
-12.69

Latest News

Latest News

BRIEF-Mayne Pharma Announces Strategic Partnership With Novast

* AGREEMENT FOR 13 US GENERIC ORAL CONTRACEPTIVE PRODUCTS, INCLUDING 5 NEW PRODUCTS NOT PREVIOUSLY MARKETED BY CO Source text for Eikon: Further company coverage:

BRIEF-Mayne Pharma Announces FDA Filing Acceptance Of E4/DRSP In U.S.

* FDA IS EXPECTED TO COMPLETE ITS REVIEW IN FIRST HALF OF CALENDAR 2021 Source text for Eikon: Further company coverage:

BRIEF-Mayne Pharma Group Executes License & Supply Deal For Novel Oral Contraceptive In Australia

* EXECUTES 20 YEAR LICENSE AND SUPPLY AGREEMENT FOR NOVEL ORAL CONTRACEPTIVE IN AUSTRALIA

BRIEF-Mithra Pharmaceuticals: Mayne Pharma Submits New Drug Application To FDA

* MAYNE PHARMA SUBMITS NEW DRUG APPLICATION FOR E4/DRSP TO FDA

BRIEF-Mayne Pharma Submits New Drug Application For E4/DRSP To FDA

* MAYNE PHARMA SUBMITS NEW DRUG APPLICATION FOR E4/DRSP TO THE FDA

BRIEF-Mayne Pharma Group Says Group CFO Nick Freeman Has Tendered Resignation

* GROUP CHIEF FINANCIAL OFFICER NICK FREEMAN HAS TENDERED HIS RESIGNATION

BRIEF-Mayne Pharma Group Says H1 Revenue From Ordinary Activities $227.2 Mln, Down 17.2%

* H1 REVENUE FROM ORDINARY ACTIVITIES $227.2 MILLION, DOWN 17.2%

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up